Transcriptional activation of hypoxia-inducible factor-1α by HDAC4 and HDAC5 involves differential recruitment of p300 and FIH-1

FEBS Letters

Volumn 583, Issue 1, 2009, Pages 55-60

  Seo, Hee Won ^a   Kim, Eun Jin ^a   Na, Hyelin ^a   Lee, Mi Ock ^a  

^a Tumor Microenvironment Global Core Research Center   (South Korea)

Author keywords

FIH; HDAC; HIF 1 ; p300

Indexed keywords

HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN FACTOR INHIBITING HIF 1; PROTEIN INHIBITOR; PROTEIN P300; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; BINDING SITE; CONTROLLED STUDY; DISSOCIATION; ENZYME ACTIVATION; ENZYME REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STABILITY;

CELL LINE; HISTONE DEACETYLASES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; P300-CBP TRANSCRIPTION FACTORS; REPRESSOR PROTEINS; TRANSCRIPTIONAL ACTIVATION;

EID: 57749177692     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2008.11.044     Document Type: Article

References (26)

1. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003) 721-732
2. Brahimi-Horn C., Mazure N., and Pouyssegur J. Signalling via the hypoxia-inducible factor-1α requires multiple posttranslational modifications. Cell Signal. 17 (2005) 1-9
3. Kaelin W.G. Proline hydroxylation and gene expression. Annu. Rev. Biochem. 74 (2005) 115-128
4. Bilton R., Trottier E., Pouyssegur J., and Brahimi-Horn M.C. ARDent about acetylation and deacetylation in hypoxia signaling. Trends Cell Biol. 16 (2006) 616-621
5. Xenaki G., Ontikatze T., Rajendran R., Stratford I.J., Dive C., Krstic-Demonacos M., and Demonacos C. PCAF is an HIF-1 alpha cofactor that regulates p53 transcriptional activity in hypoxia. Oncogene 27 (2008) 5785-5796
6. Mahon P.C., Hirota K., and Semeza G.L. FIH-1: a novel protein that interacts with HIF-1 and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15 (2001) 2675-2686
7. Lando D., Peet D.J., Gorman J.J., Whelan D.A., and Whitelaw M.L. Asparagine hydroxylation of the HIF transactivation domain. Science 295 (2002) 858-861
8. Lando D., Peet D.J., Gorman J.J., Whelan D.A., Whitelaw M.L., and Bruick R.K. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of HIF. Genes Dev. 16 (2002) 1466-1471
9. De Ruijter A.J., van Gennip A.H., Caron H.N., Kemp S., and van Kuilenburg A.B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370 (2003) 737-749
10. Gregoretti I.V., Lee Y.M., and Goodson H.V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 338 (2004) 17-31
11. Saverio M., and Pier G.P. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Rev. Cancer 6 (2006) 38-51
12. Glozak M.A., and Seto E. Histone deacetylases and cancer. Oncogene 26 (2007) 5420-5432
13. Kim M.S., et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 7 (2001) 437-443
14. Yoo Y.G., Kong G., and Lee M.O. Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1 alpha protein by recruiting histone deacetylase 1. EMBO J. 25 (2006) 1231-1241
15. Kong X., Lin Z., Liang D., Fath D., Sang N., and Caro J. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor-1 alpha. Mol. Cell Biol. 26 (2006) 2019-2028
16. Fath D.M., et al. Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha. J. Biol. Chem. 281 (2006) 13612-13619
17. Qian D.Z., Kachhap S.K., Collis S.J., Verheul H.M., Carducci M.A., Atadja P., and Pili R. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor-1 alpha. Cancer Res. 66 (2006) 8814-8821
18. Ito A., Kawaguchi Y., Lai C.H., Kovacs J.J., Higashimoto Y., Appella E., and Yao T.P. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 21 (2002) 6236-6245
19. Yoo Y.G., et al. Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1 alpha through activation of mitogen-activated protein kinase pathway. J. Biol. Chem. 278 (2003) 39076-39084
20. Kim S.H., Jeong J.W., Park J.A., Lee J.W., Seo J.H., Jung B.K., Bae M.K., and Kim K.W. Regulation of the HIF-1 alpha stability by histone deacetylases. Oncol. Rep. 17 (2007) 647-651
21. Kato H., Tamamizu-Kato S., and Shibasaki F. Histone deacetylase 7 associates with hypoxia-I inducible factor-1 alpha and increases transcriptional activity. J. Biol. Chem. 279 (2004) 41966-41974
22. Epstein A.C.R., Elegans C., et al. EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107 (2001) 43-44
23. Shin D.H., Chun Y.S., Lee D.S., Huang L.E., and Park J.W. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood 111 (2008) 3131-3136
24. Fukuba H., et al. Siah-1 facilitates ubiquitination and degradation of FIH. Biochem. Biophys. Res. Commun. 353 (2007) 324-329
25. Cockman M.E., et al. Posttranslational hydroxylation of ankyrin repeats in IkappaB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH). Proc. Natl. Acad. Sci. USA 103 (2006) 14767-14772
26. Ozdaǧ H., et al. Differential expression of selected histone modifier genes in human solid cancers BMC genomics 7 (2006) 90